ISRCTN57325925已完成未知
Multicenter study to evaluate the clinical and cost-effectiveness of a youth culturally adapted therapy (YCMAP)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 684
研究概览
简要总结
2022 Protocol article in https://pubmed.ncbi.nlm.nih.gov/35568489/ (added 09/04/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 12-18 years
- •2. Presenting to the participating GPs, emergency departments or admitted after an episode of self-harm to the participating hospitals or self-referrals
- •3. History of recent self-harm, defined as self-harm occurring within the last 3 months (from the initial identification of a potential participant)
- •4. Participants living within the catchment area of the participating practices and hospitals
- •5. Not needing inpatient psychiatric treatment
排除标准
- •1. Severe mental illness (such as psychotic disorder) as self-harm commonly co-occurs with other mental health difficulties
- •2. Conditions limiting engagement with assessment or intervention, including developmental and communication disorders, intellectual disabilities and autistic spectrum disorders
- •3. Temporary resident unlikely to be available for follow up
研究者
相似试验
进行中（未招募）
不适用
TRABIO: registry for documenting treatment success after kidney transplant rejectionsKidney biopsies for suspected acute and chronic rejections in patients with kidney graftsUrological and Genital DiseasesISRCTN78772632Chiesi (Germany)800
已完成
3 期
Vaccine Response On/off Methotrexate (VROOM): does temporarily suspending methotrexate treatment for two weeks enhance COVID-19 vaccine response?ISRCTN11442263CTU0373383
已完成
3 期
Trial investigating the effectiveness of a medical device (Alpha-Stim AID) for the treatment of depressive symptoms for patients in primary careISRCTN11853110niversity of Nottingham236
进行中（未招募）
不适用
Does screening with the Galleri test in the NHS reduce the likelihood of a late-stage cancer diagnosis?Multi cancer early detection in people without symptomsCancerISRCTN91431511GRAIL Bio UK Ltd.140,000
进行中（未招募）
不适用
Autologous stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing-remitting multiple sclerosisMultiple sclerosisRelapsing-remitting multiple sclerosisNervous System DiseasesISRCTN88667898Sheffield Teaching Hospitals NHS Foundation Trust198